{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679139748992.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1248/cpb.50.1349"}},{"identifier":{"@type":"COI","@value":"1:CAS:528:DC%2BD38XosFymtrY%3D"}},{"identifier":{"@type":"PMID","@value":"12372861"}},{"identifier":{"@type":"NDL_BIB_ID","@value":"6312821"}},{"identifier":{"@type":"URI","@value":"http://id.ndl.go.jp/bib/6312821"}},{"identifier":{"@type":"URI","@value":"https://ndlsearch.ndl.go.jp/books/R000000004-I6312821"}},{"identifier":{"@type":"URI","@value":"http://www.jstage.jst.go.jp/article/cpb/50/10/50_10_1349/_pdf"}},{"identifier":{"@type":"NAID","@value":"110003615075"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2003088708"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@language":"en","@value":"Studies on Non-Thiazolidinedione Antidiabetic Agents. 1. Discovery of Novel Oxyiminoacetic Acid Derivatives."}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"A novel series of oxyiminoacetic acid derivatives were synthesized in an effort to develop a potent antidiabetic agent, which does not contain the 2,4-thiazolidinedione moiety. These compounds were evaluated for glucose and lipid lowering effects in genetically obese and diabetic KKA<sup>y</sup> mice. Several of the compounds showed strong antidiabetic activity, including functional potency at peroxisome proliferator-activated receptor (PPAR)-γ. (<i>Z</i>)-2-[4-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino]-2-(4-phenoxyphenyl)acetic acid (25) significantly reduced plasma glucose (33%, <i>p</i><0.01) and plasma triglycelide levels (43%, <i>p</i><0.01) even at a dosage of 0.001% in diet. Pharmacokinetic analyses of 25 are also reported."}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410282679139393024","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000003031335"}],"foaf:name":[{"@language":"en","@value":"Imoto Hiroshi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Takeda Chemical Industries, Ltd., Pharmaceutical Research Division"}]},{"@id":"https://cir.nii.ac.jp/crid/1410001205808957186","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000004470426"}],"foaf:name":[{"@language":"en","@value":"Imamiya Eikoh"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Takeda Chemical Industries, Ltd., Pharmaceutical Research Division"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679139393027","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000005134934"}],"foaf:name":[{"@language":"en","@value":"Sugiyama Yasuo"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Takeda Chemical Industries, Ltd., Pharmaceutical Research Division"}]},{"@id":"https://cir.nii.ac.jp/crid/1420564276169474944","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"00386541"},{"@type":"NRID","@value":"1000000386541"},{"@type":"NRID","@value":"9000005134931"},{"@type":"NRID","@value":"9000006014901"},{"@type":"NRID","@value":"9000002371922"},{"@type":"NRID","@value":"9000408492594"},{"@type":"NRID","@value":"9000005139140"},{"@type":"NRID","@value":"9000254704701"},{"@type":"NRID","@value":"9000410893874"},{"@type":"NRID","@value":"9000252127912"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0129913"}],"foaf:name":[{"@language":"en","@value":"Momose Yu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Takeda Chemical Industries, Ltd., Pharmaceutical Research Division"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679139748992","@type":"Researcher","foaf:name":[{"@language":"en","@value":"Kimura Hiroyuki"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Takeda Chemical Industries, Ltd., Pharmaceutical Research Division"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282679139748865","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000005134939"}],"foaf:name":[{"@language":"en","@value":"Sohda Takashi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Takeda Chemical Industries, Ltd., Pharmaceutical Research Division"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00092363"},{"@type":"EISSN","@value":"13475223"},{"@type":"NDL_BIB_ID","@value":"000000120512"},{"@type":"ISSN","@value":"00092363"},{"@type":"LISSN","@value":"00092363"},{"@type":"NCID","@value":"AA00602100"}],"prism:publicationName":[{"@language":"ja","@value":"ＣＨＥＭＩＣＡＬ　＆　ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ　ＢＵＬＬＥＴＩＮ"},{"@language":"en","@value":"Chemical and Pharmaceutical Bulletin"},{"@language":"en","@value":"Chem. Pharm. Bull."},{"@language":"en","@value":"CHEMICAL & PHARMACEUTICAL BULLETIN"},{"@language":"ja","@value":"Ｃｈｅｍ．　Ｐｈａｒｍ．　Ｂｕｌｌ．"}],"dc:publisher":[{"@language":"en","@value":"The Pharmaceutical Society of Japan"},{"@language":"ja","@value":"公益社団法人 日本薬学会"}],"prism:publicationDate":"2002","prism:volume":"50","prism:number":"10","prism:startingPage":"1349","prism:endingPage":"1357"},"reviewed":"false","url":[{"@id":"http://id.ndl.go.jp/bib/6312821"},{"@id":"https://ndlsearch.ndl.go.jp/books/R000000004-I6312821"},{"@id":"http://www.jstage.jst.go.jp/article/cpb/50/10/50_10_1349/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2003088708"}],"availableAt":"2002","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=antidiabetic%20agent","dc:title":"antidiabetic agent"},{"@id":"https://cir.nii.ac.jp/all?q=oxyiminoacetic%20acid","dc:title":"oxyiminoacetic acid"},{"@id":"https://cir.nii.ac.jp/all?q=type%202%20diabetes","dc:title":"type 2 diabetes"},{"@id":"https://cir.nii.ac.jp/all?q=peroxisome%20proliferator-activated%20receptor","dc:title":"peroxisome proliferator-activated receptor"},{"@id":"https://cir.nii.ac.jp/all?q=KKA%3Csup%3Ey%3C/sup%3E%20mice","dc:title":"KKA<sup>y</sup> mice"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011143932945920","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Comparison of efficacy, secondary failure rate, and complications of sulfonylureas"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145684780288","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Monitoring and controlling the patient with non-insulin-dependent diabetes mellitus"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145766488832","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"A new genetically obese-hyperglycemic rat (Wistar fatty)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619104871424","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"EFFECT OF TWO YEARS OF STRICT METABOLIC CONTROL ON PROGRESSION OF INCIPIENT NEPHROPATHY IN INSULIN-DEPENDENT DIABETES"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620507335936","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620993009152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Ciglitazone, a New Hypoglycemic Agent: I. Studies in ob/ob and db/db Mice, Diabetic Chinese Hamsters, and Normal and Streptozotocin-Diabetic Rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621615134976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094061424768","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094176124416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"(3-Substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574094945478400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"<i>N</i>-(2-Benzoylphenyl)-<scp>l</scp>-tyrosine PPARγ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095537392640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Diabetes Mellitus and Its Degenerative Complications: A Prospective Study of 4,400 Patients Observed Between 1947 and 1973"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569536471040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570180253824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Isoxazolidine-3,5-dione and Noncyclic 1,3-Dicarbonyl Compounds as Hypoglycemic Agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570842064640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Structure−Activity Relationship between Peroxisome Proliferator-Activated Receptor γ Agonism and the Antihyperglycemic Activity of Thiazolidinediones"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519642516480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hypoglycemic Activity of a Series of α-Alkylthio and α-Alkoxy Carboxylic Acids Related to Ciglitazone"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520947939584","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Potent Antidiabetic Thiazolidinedione with Unique Peroxisome Proliferator-activated Receptor γ-activating Properties"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995197336064","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995429999104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hyperinsulinemia as an Independent Risk Factor for Ischemic Heart Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995806729088","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A New Genetically Obese-Hyperglycemic Rat (Wistar Fatty)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468845395200","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470526468864","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945205044352","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Synthetic ligands for PPARγ - review of patent literature 1994 - 1999"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419434460160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of Troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419437580160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Lymphocytic Infundibuloneurohypophysitis as a Cause of Central Diabetes Insipidus"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420943907456","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"<i>N</i>-(2-Benzoylphenyl)-<scp>l</scp>-tyrosine PPARγ Agonists. 3. Structure−Activity Relationship and Optimization of the <i>N</i>-Aryl Substituent"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894966219264","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825896128721664","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Implications of the Diabetes Control and Complications Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368964647936","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"[[.omega.-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369271479424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study."}]},{"@id":"https://cir.nii.ac.jp/crid/1363388844012201472","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Diabetes Mellitus and Its Degenerative Complications: A Prospective Study of 4,400 Patients Observed Between 1947 and 1973"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845493350272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319180253312","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"(−)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic Acid [(−)DRF 2725]:  A Dual PPAR Agonist with Potent Antihyperglycemic and Lipid Modulating Activity"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951793595379072","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Diabetes, Exercise, and Atherosclerosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794136297728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Novel Euglycemic and Hypolipidemic Agents. 1"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794408692736","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"<i>N</i>-(2-Benzoylphenyl)-<scp>l</scp>-tyrosine PPARγ Agonists. 2. Structure−Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268952529280","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"Ciglitazone, a new hypoglycemic agent. I. Studies in ob/ob and db/db mice, diabetic Chinese hamsters, and normal and streptozotocin-diabetic rats"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269773112576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Molecular Design, Synthesis, and Hypoglycemic Activity of a Series of Thiazolidine-2,4-diones"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270291782272","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271192534912","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Differential expression and activation of a family of murine peroxisome proliferator-activated receptors."}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204162007040","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Studies on antidiabetic agents. II. Synthesis of 5-(4-(1-methylcyclohexylmethoxy)-benzyl)thiazolidine-2,4-dione (ADD-3878) and its derivatives."},{"@value":"Studies on antidiabetic agents. II. Synthesis of 5-[4-(l-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204171225472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Studies on Non-Thiazolidinedione Antidiabetic Agents. 3. Preparation and Biological Activity of the Metabolites of TAK-559"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204625709952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Licorice Flavonoids Suppress Abdominal Fat Accumulation and Increase in Blood Glucose Level in Obese Diabetic KK-Ay Mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206291847680","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"General Survey of Diabetic Features of Yellow KK Mice"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679120081408","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"<i>N</i>,<i>N</i>-Di- and <i>N</i>,<i>N</i>,<i>C</i>-Trialkylation of α-Sulfoximino Esters"},{"@value":"N,N-Di- and N,N,C-Trialkylation of α-Sulfoximino Esters"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679137086720","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Studies on Antidiabetic Agents. X. Synthesis and Biological Activities of Pioglitazone and Related Compounds."}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679139393024","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Studies on Non-Thiazolidinedione Antidiabetic Agents. 2. Novel Oxyiminoalkanoic Acid Derivatives as Potent Glucose and Lipid Lowering Agents."}]},{"@id":"https://cir.nii.ac.jp/crid/1570009749914397952","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1570009751756853632","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1570009751788188544","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1570009751798280064","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1570291224754905344","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1570291225034929664","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1570291226772675072","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1570572701708818688","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1570572701756953216","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1570854176693230080","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1571135650803908736","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1571417126679744896","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1571980074895193728","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1572261551588729344","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1572543024704794496","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1572543024704795776","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1572543024848613760","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1572543026586360704","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1573105974279190400","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1573387449778744960","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1573668924161896448","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1573668924611637376","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1573668924755456640","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1573668926512445312","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1573950399803809152","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1573950401469914112","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1574231874708877184","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1574231876447054080","@type":"Article","relationType":["cites"]},{"@id":"https://cir.nii.ac.jp/crid/1574231877205473408","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Studies on Antidiabetic Agents. X. Synthesis and Biological Activities of Pioglitazone and Related Compounds"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0015111886"},{"@type":"NDL_SEARCH","@value":"oai:ndlsearch.ndl.go.jp:R000000004-I6312821"},{"@type":"CROSSREF","@value":"10.1248/cpb.50.1349"},{"@type":"PUBMED","@value":"12372861"},{"@type":"CIA","@value":"110003615075"},{"@type":"CROSSREF","@value":"10.1248/cpb.51.138_references_DOI_Kugj30JKkQPtUmCorBiErziwr1i"},{"@type":"CROSSREF","@value":"10.1246/bcsj.20120195_references_DOI_Kugj30JKkQPtUmCorBiErziwr1i"},{"@type":"CROSSREF","@value":"10.1248/cpb.52.120_references_DOI_Kugj30JKkQPtUmCorBiErziwr1i"},{"@type":"CROSSREF","@value":"10.1248/bpb.27.1775_references_DOI_Kugj30JKkQPtUmCorBiErziwr1i"}]}